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Age-related macular degenerationRetinal degenerations are a group of clinically and genetically heterogeneous disorders character-
ised by progressive loss of vision due to neurodegeneration. The retina is a highly specialised tissue
with a unique architecture and maintaining homeostasis in all the different retinal cell types is cru-
cial for healthy vision. The retina can be exposed to a variety of environmental insults and stress,
including light-induced damage, oxidative stress and inherited mutations that can lead to protein
misfolding. Within retinal cells there are different mechanisms to cope with disturbances in prote-
ostasis, such as the heat shock response, the unfolded protein response and autophagy. In this
review, we discuss the multiple responses of the retina to different types of stress involved in retinal
degenerations, such as retinitis pigmentosa, age-related macular degeneration and glaucoma.
Understanding the mechanisms that maintain and re-establish proteostasis in the retina is impor-
tant for developing new therapeutic approaches to ﬁght blindness.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The vertebrate eye is one of the most sophisticated organs in
biology and initiates our most precious sense, vision. At the back
of the eye, the retina captures light and transmits electrical im-
pulses through the optic nerve to the visual cortex in the brain.
The mammalian retina is composed of eight different layers that
contain a specialised network of approximately 55 neuronal types
which process visual information (Fig. 1) [1]. The main light-
detecting cells in the retina are the photoreceptors, rods and cones.
Rods are approximately 20 times more numerous than cones and
are responsible for detecting low levels of light. Cones detect much
higher levels of light and are responsible for colour and daytime vi-
sion. The outer nuclear layer (ONL) contains the photoreceptor cell
bodies, and the photoreceptor visual pigments, rod opsin for rods
and cone opsin for cones, are tightly packed into ﬂattened mem-
brane disks in the outer segments (OS). The inner segment (IS) of
the photoreceptor contains the main biosynthetic machinery such
as the endoplasmic reticulum (ER) and is rich in mitochondria [2].
The biogenesis, post-translational modiﬁcations and quality
control of many OS proteins, including opsin, take place in theER. The photoreceptor disks are continually replenished, which
leads to a high turnover of proteins, and places a strain on the ER
and its quality control machinery. Microvilli from the retinal pig-
ment epithelium (RPE) cells contact the photoreceptor OS tips
and phagocytose the shed material, prior to lysosomal degradation
within the RPE. The RPE acts as a support for the retina, transport-
ing nutrients and water and is important in for the recycling of 11-
cis-retinal, known as the visual cycle [3]. The outer plexiform layer
(OPL) consists of the processes and synaptic terminals of photore-
ceptors, where they contact the horizontal cell and bipolar cell
dendrites. The inner nuclear layer (INL) contains horizontal, bipolar
and amacrine cell bodies. Horizontal cells integrate the signal from
the rods and cones by providing an inhibitory feedback to regulate
photoreceptor function [4]. Bipolar cells receive the signal from
photoreceptors or horizontal cells and contact the retinal ganglion
cells (RGCs) [5]. The inner plexiform layer (IPL) is composed of the
synapses of bipolar and RGCs and the ganglion cell layer (GCL) con-
tains the nuclei of RGCs and their axons that form the output from
the retina to the brain through the optic nerve. In addition to the
neuronal cells in the retina, there are retinal glia cells; the Müller
cells, microglia and astrocytes. Müller glia surround the neuronal
cell bodies within the retina and are crucial for neuronal health
and maintenance [6]. Due to this complex architecture and high
metabolic demand, the retina needs constant maintenance to en-
Fig. 1. Structure of the mammalian retina. Schematic cross section representing the
different cell types and layers of the retina. The choroid (CRD) containing red blood
cells (RBCs) is found at the very back of the eye and is separated from the retinal
pigmented epithelia (RPE) by the Bruch’s membrane (BM). The RPE extends
microvilli (MV) that facilitate the interaction between the RPE and photoreceptors
(PRs). Cone (CPR) and rod (RPR) photoreceptors contain the cone and rod outer and
inner segments (COS, ROS and IS respectively), the outer nuclear layer (ONL) and
outer plexiform layer (OPL), which contains the synapses of the photoreceptors,
horizontal cells (HCs) and bipolar cells (BCs). The inner nuclear layer (INL) contains
the cell bodies of the horizontal, bipolar and amacrine cells (AmCs). The inner
plexiform layer (IPL) is formed of the connections between bipolar and amacrine
cells to the retinal ganglion cells (RGCs), in the ganglion cell layer (GCL).
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evolution retinal cells have developed adaptive responses to a vari-
ety of insults, which cooperate to restore cell homeostasis, and in-
crease the resistance of the tissue to further damage. Cell stress can
arise in many forms in the retina causing the death of several dif-
ferent neuronal types and leading to blindness. This review will
discuss the molecular and cellular mechanisms that are present
in the retina to deal with cell stress, in particular protein misfold-
ing problems such as those caused by mutations in rhodopsin.
1.1. Photoreceptor degeneration and retinitis pigmentosa
Photoreceptors are particularly susceptible to cellular stress and
loss of photoreceptors due to degeneration is a major cause of
blindness. Photoreceptor degenerations are possibly the most het-
erogeneous inherited disorder known in man, with over 140 differ-
ent causative genes identiﬁed [7]. These inherited disorders can
affect either rods or cones primarily, as in retinitis pigmentosa
(RP) or cone dystrophy respectively, or both simultaneously, as in
Leber congenital amaurosis (LCA). Electroretinogram (ERG) mea-
surements can record the electrical response of the retina, and
the measurements can be separated into rod (scotopic) or cone
(photopic) responses. In this way ERGs can be used to identify
the primary cell type affected in retinal degenerations. For exam-
ple, RP classically involves the loss of the scotopic response,
whereas in LCA, which is an early-onset, extreme retinal degener-
ation, both the photopic and scotopic responses are lost.
RP is one of the most common forms of inherited retinal degen-
eration comprising a group of retinal disorders that typically in-
volve progressive degeneration of rod photoreceptor cells
followed by secondary cone photoreceptor death. The ﬁrst symp-
tom is night blindness, due to the dysfunction of rod cells, which
later advances to the loss of peripheral vision (tunnel vision). RP
progresses towards the macula at the centre of the retina with
the death of cone cells resulting in loss of central vision and partial
or complete blindness by middle age [8]. Clinical examinations of
the retinae of RP patients show abnormal fundi with pigmented
bone-spicule deposits, attenuated retinal vessels and pallor of the
optic nerve. The prevalence of RP is 1 in 4000 people worldwide,
resulting in over 1.5 million visually impaired patients. The inher-
itance patterns of RP are varied; 15–25% are autosomal dominant
(adRP), 5–25% are autosomal recessive (arRP), 5–15% are X-linked
(XLRP), while the remaining 35–50% cannot be easily classiﬁed
genetically [9]. To date, 27 adRP, 36 arRP and six XLRP genetic loci
have been identiﬁed, often with overlap [10]. RP can also be syn-
dromic, where other organs are also affected, such in Usher’s syn-
drome which is associated with hearing impairment and RP
symptoms [11].
1.1.1. Rhodopsin RP
Rhodopsin, the light-absorbing photopigment of rod cells, is the
archetypal G-protein coupled receptor (GPCR) and therefore one of
the best characterised. Rhodopsin is composed of the 348 amino
acid apoprotein rod opsin, which is covalently linked with the
chromophore 11-cis-retinal, an analogue of vitamin A. Rhodopsin
undergoes multiple post-translational modiﬁcations such as N-
linked glycosylation, disulphide bond formation, acetylation, palm-
itoylation, phosphorylation and ubiquitylation. Each of these post-
translational modiﬁcations is either essential for the maintenance
of rod OS structure or the ﬁne-tuning of rhodopsin function [12].
Rod opsin is synthesised on the rough ER membranes before transit
to the Golgi and trafﬁc to the OS disks in rod cells or to the plasma
membrane (PM) in heterologous expression systems.
Rhodopsin was the ﬁrst RP gene identiﬁed [13]. To date, over
200 rhodopsin point mutations have been described which account
for approximately 25% of all adRP cases. Six classes of rhodopsinmutants have been proposed, based on their cellular and biochem-
ical characteristics [14]. Class I mutants fold normally but are not
trafﬁcked to the OS correctly, while class II mutants are misfolded
and retained in the ER. The remaining mutations are classiﬁed
according to their effects on endocytosis, opsin stability, increased
transducin activation and constitutive activation [14]. The class II
P23H mutation is the most common mutation found in North
America and is the best studied. The role of the proteostasis
machinery in rhodopsin biogenesis and quality control of mutant
rhodopsin will be discussed in detail below.
1.2. Light-induced damage
The retina is a transparent tissue, since visible light needs to
penetrate the inner retina, where the RGCs and bipolar cells reside,
to reach the outer retina and the photoreceptors. While an appro-
priate amount of visible light is needed to initiate phototransduc-
tion, too much light entering the retina can also induce damage;
therefore, the eye has developed natural mechanisms to restrict
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Ultraviolet (UV) light (both UV-A and UV-B) together with visible
light of 500 nm wavelength (blue light) have been linked to ret-
inal degeneration. Acute bright light exposure can damage both the
RPE and photoreceptors, even in control animals. Light-induced
damage can be multifactorial and can arise from environmental in-
sults, genetic diseases as well as aging, since increased light levels
throughout life can exacerbate age-related damage [15]. Retinal
topography also plays an important role in light tolerance, with
the inferior hemisphere being more sensitive in light-induced
damage than the superior [16]. There is growing evidence implicat-
ing the release of all-trans retinal from light-activated rhodopsin as
a mediator of acute photodamage to the retina, along with the
excessive build-up of (photo) toxic components in the RPE follow-
ing disk phagocytosis [17,18]. All-trans retinal is a potent photo-
sensitizer and upon photoexcitation by light, when oxygen is
present, can generate reactive oxygen species such as singlet oxy-
gen, superoxide and hydrogen peroxide, which are highly toxic
leading to oxidative stress and consequently to lipid, protein and
DNA damage. Light-induced damage can be more pronounced
when genetic defects are associated with decreased pigmentation,
increased formation or slow removal of retinoids, inefﬁcient RPE
phagocytosis, defects in the phototransduction machinery or with
problems of OS stability and turnover. Studies in animal models
with some of these genetic defects have shown that dark-rearing
can slow or prevent retinal degeneration, suggesting that light
management should be considered as part of the treatment for
some patients with retinal degeneration [19].
1.3. Retinal ganglion cell related-retinal degeneration
RGCs are responsible for transmitting visual information from
the retina to the visual cortex in the brain. Due to the anatomic dis-
tance between the retina and the brain, the long axons of RGCs
must transport metabolites and organelles via axonal transport, a
process with a high energy demand. Mitochondria, which are more
abundant in the unmyelinated parts of the axons, generate adeno-
sine triphosphate (ATP) that is needed to propagate the action po-
tential to the brain. Therefore, disturbances of axonal transport or
mitochondrial function can have severe consequences for RGC
function and viability [20,21]. Glaucoma is characterised by the
progressive degeneration of RGCs and the optic nerve head leading
to constricted visual ﬁelds, possibly related to increase intraocular
pressure (IOP) causing pressure on the axons in the lamina cribrosa
[22]. While the exact mechanisms of RGC death in glaucoma re-
main relatively unknown, there is a clear link between mitochon-
drial dysfunction and selective RGC death, since mitochondrial
optic neuropathies such as Leber hereditary optic neuropathy
(LHON) and autosomal dominant optic atrophy (adOA) primarily
affect RGCs [23–25].
1.4. RPE-related retinal degeneration
The RPE is a monolayer of supporting epithelial cells whose
main functions are maintaining the posterior blood retinal barrier
(BRB), recycling of visual pigment, phagocytosis of photoreceptor
OS and neurotrophic factor secretion. Because of the intimate rela-
tionship between photoreceptors and RPE cells, RPE dysfunction
can have a deleterious effect on photoreceptor viability. Vision loss
can occur when RPE cell death or malfunction increases photore-
ceptor vulnerability [3]. For example, in models of RP where RPE-
speciﬁc genes are mutated, photoreceptor degeneration can occur
either by accumulation of toxic by-products from the visual cycle,
the loss of the essential factors, such as 11-cis-retinal, or by the loss
of mechanical support that the RPE confers to photoreceptors [17].
Furthermore, the function and survival of the RPE is compromisedin age-related macular degeneration (AMD), the leading cause of
blindness affecting people over 65 years old. AMD results in loss
of central vision due to degeneration of the macula in the central
region of the retina and manifests in two forms, wet and dry. While
the wet form is associated with neovascularisation, the dry form is
characterised by the appearance of extracellular deposits called
drusen, which accumulate between the RPE and the Bruch’s mem-
brane leading to RPE cell death. Although it remains uncertain if
drusen are the cause or consequence of RPE dysfunction, their
presence blocks the diffusion of nutrients and regulatory sub-
stances, which are vital for RPE and photoreceptor survival. The
accumulation of lipofuscin in the RPE, an auto-ﬂuorescent pigment,
which is implicated in several retinal dystrophies, is thought to be
a risk factor for RPE degeneration in aging and in AMD [18].
1.5. Vascular defects
The retina, as part of the central nervous system (CNS), is im-
mune-privileged and protected by the BRB, which stringently con-
trols the exchange of molecules between the circulation and the
retina [26]. Furthermore, parts of the retina, such as the outer ret-
ina that contain the RPE and photoreceptors, need to remain avas-
cular in order to allow efﬁcient light transmission and high acuity.
Therefore, the nutritional and oxygen needs of the outer retina are
met by the choriocapillaris of the adjacent choroid (choroid circu-
lation), while in the inner retina these are met by the retinal vas-
culature. The requirement of high oxygen supply in the retina
and the retinal vasculature can make the retina vulnerable to vas-
cular diseases. Retinal neovascularisation is a major cause of vision
loss where new blood vessels penetrate the neuroretina from the
choroid or retinal vessels branch out inside the neuroretina or fuse
with the choroidal cells (anastomosis), destroying underlying neu-
ronal tissue. Neovascularisation in response to injury and disease
can occur when there is an oxygen imbalance or BRB breakdown
and/or dysregulation of pro-angiogenic factors such as the vascular
endothelial growth factor (VEGF) [27]. For example, at the late
stages of wet AMD, the posterior BRB has already been compro-
mised and choroidal vessels invade the RPE and grow into the ret-
ina. In diabetic retinopathy, hyperglycemia initiates microvascular
occlusion resulting in capillary non-perfusion and hypoxia which
subsequently triggers retinal neovascularisation [28].
2. The role of the proteostasis network in retinal degeneration
Protein folding is a complicated but imperfect process, for
example as much as 30% of newly synthesised proteins are de-
graded before they attain their mature functional conformation
[29]. To cope with misfolded proteins cells have evolved many
mechanisms, including the heat shock response (HSR), the ubiqui-
tin–proteasome system (UPS), the unfolded protein response (UPR)
and ER-associated degradation (ERAD). Collectively these are re-
ferred to as the protein homeostasis (or proteostasis) network
(Fig. 2). The function of the proteostasis network is to generate
and maintain correctly folded proteins, and to remove, sequester
and destroy misfolded proteins which affect normal function
[30]. Within the cell, a set of highly evolutionarily-conserved pro-
teins known as molecular chaperones promote and maintain prop-
er protein folding [31]. Molecular chaperones have multiple
functions related to proteostasis; these include guidance of trans-
located proteins across membranes, disassembling oligomeric
structures, facilitating degradation of damaged or misfolded pro-
teins, vesicular trafﬁcking and signal transduction [32–34]. Molec-
ular chaperone proteins prevent misfolding by binding and
shielding hydrophobic regions of the nascent polypeptide, which
are normally buried in mature folded proteins [31,32]. Chaperone
activity is frequently governed by cycles of client protein binding
Fig. 2. Photoreceptor proteostasis networks. Schematic showing the proteostasis networks in a rod photoreceptor that deal with misfolded proteins, such as P23H rod opsin
(mutant rhodopsin in green), or cell stress. (A) ERAD. Misfolded proteins are detected by the ER quality control machinery (including BiP, EDEM1, VCP) and shuttled to the
cytoplasm by the retrotranslocon where they are ubiquitylated before being degraded by the proteasome. (B) The UPR. Misfolded proteins, such as mutant rod opsin, in the ER
are recognised by three sensors: IRE1, PERK and ATF6 that inhibit protein synthesis and stimulate the production of chaperones and the ERADmachinery (see text for details).
(C) Autophagy. Misfolded proteins can be degraded by three modes of autophagy: macroautophagy, microautophagy or CMA. (D) The HSR. Molecular chaperones Hsp70,
Hsp40 and Hsp90 can exist in a complex in the cytosol with their transcription factor HSF1. Upon binding misfolded proteins, Hsp70, Hsp40 and Hsp90 dissociate from HSF1,
which can trimerise and activate via phosphorylation. This results in trafﬁc to the nucleus leading to increased chaperone expression.
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exchange. Several co-chaperone proteins regulate this process,
for example DnaJ (Hsp40) co-chaperones stimulate ATP hydrolysisby Hsp70 proteins. Many molecular chaperones are also known as
the heat shock proteins (Hsps), having been originally discovered
as upregulated factors during the HSR. The HSR is mediated by heat
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(HSF1). Under normal conditions, HSF1 is bound by the molecular
chaperones Hsp70 and Hsp90 (Fig. 2). In the presence of cellular
stress, the molecular chaperones are recruited to misfolded pro-
teins, thus releasing HSF1. Activation via phosphorylation and tri-
merisation results in HSF1 trafﬁcking to the nucleus where it can
further upregulate molecular chaperone expression [35].
The cell keeps a tight regulation of the protein folding capacity
in the ER by the activation of intracellular signal transduction path-
ways that together constitute the UPR (Fig. 2). The accumulation of
unfolded proteins in the lumen of the ER initiates the UPR, which
responds to alleviate stress by upregulating the protein folding
and degradation capacity and inhibiting protein synthesis, eventu-
ally restoring the balance. At least three distinct branches of the
UPR regulate the expression of numerous genes that maintain
homeostasis in the ER or induce apoptosis if ER stress remains un-
changed. Three ER-resident transmembrane proteins have been
identiﬁed: the kinase and endoribonuclease inositol requiring en-
zyme-1 (IRE1), the double-stranded RNA-activated protein kinase
(PKR)-like ER kinase (PERK) and the basic leucine-zipper activating
transcription factor 6 (ATF6). The activation of the three branches
depends on BiP, an Hsp70 molecular chaperone located in the lu-
men of the ER that binds newly synthesised proteins as they are
translocated into the ER and maintains them in a state competent
for subsequent folding and oligomerization. Luminal domains of
IRE1, ATF6 and PERK interact with BiP in unstressed cells, whereas
perturbation of protein folding titrates BiP away from association
with these sensors, freeing them for activation and induction of
the UPR [36–38].
Under stress conditions PERK phosphorylates the eukaryotic
translation initiation factor 2 subunit a (eIF2a), reducing protein
synthesis to prevent further increase of nascent proteins. ATF6
activation leads to the expression of target genes encoding chaper-
ones [39]. IRE1 activation initiates the non-conventional splicing of
XBP-1 (X-box DNA binding protein), a UPR speciﬁc b-ZIP transcrip-
tion factor that binds to ER-stress responsive genes (ERSE). Many of
these genes are part of the ERAD mechanism, thereby stimulating
efﬁcient protein degradation [40].
Degradation of misfolded proteins by ERAD can be divided into
three steps: recognition of misfolded proteins in the ER, retrotrans-
location into the cytosol and ubiquitin dependent-degradation via
the UPS (Fig. 2) [41]. For glycoproteins, recognition is achieved via
UDP-glucose glycoprotein:glucosyltransferase (UGGT) which de-
tects changes in the glycan structure, such as immature glycans
and allows proteins to switch from the calnexin (Cnx)/calreticulin
(Crt) cycle to degradation via ER degradation enhancing mannosi-
dase a-like 1 (EDEM1) [42]. Since the UPS is located in the cytosol,
ERAD substrates have to pass through a protein channel (retrotran-
slocon channel) found in the ER membrane for transport to the
cytoplasm. While the exact proteins that form the translocon re-
main unknown, the protein Sec61 complex is a possible candidate
since it is the major component of the translocation channel that
imports polypeptides into the ER [43]. Another possibility is the
protein Derlin-1 since studies have shown that it interacts with
several ERAD substrates and that its depletion can induce the
UPR [44,45]. Finally, as nascent polypeptides enter the ER in an un-
folded conformation, this would suggest that dislocation of ERAD
substrates requires unfolding, including reduction of disulphide
bonds [46]. While in the retrotranslocon, the protein needs a driv-
ing force in order to be pulled through the channel which is pro-
vided by the Cdc48p/p97/VCP ATPase using the energy from ATP
hydrolysis for substrate extraction [47]. Once the substrate reaches
the cytoplasmic face of the ER it needs to be targeted for degrada-
tion by the addition of four or more molecules of ubiquitin by ubiq-
uitin ligases. The ubiquitylated protein is then degraded by the
proteasome.An alternative degradation pathway is autophagy, which in-
volves the disposal of damaged proteins or entire organelles by
the hydrolases present in high concentrations in lysosomes
(Fig. 2). Three pathways of autophagy exist, macroautophagy,
microautophagy and chaperone-mediated autophagy (CMA) [48].
Macroautophagy involves the sequestration of substrates or organ-
elles with a double-membrane structure called the autophagosome
that is transported through the cytoplasm to the lysosome. Fusion
of the two membranes allows the autophagosome to enter the
lysosome [48]. Microautophagy involves the direct sequestration
of substrate material via the invagination of their membranes.
CMA involves the selective recognition of cytosolic proteins by
the Hsc70 complex and their targeting to the lysosome for degra-
dation [49].
The disruption of proteostasis has been implicated in several
retinal diseases, such as retinitis pigmentosa, age-related macular
degenerations and glaucoma.
2.1. Proteostasis mechanisms and RP
The majority of rod opsin mutations, including P23H, lead to the
misfolding of rod opsin and to its accumulation within the cell,
with detrimental effects on photoreceptor function and viability.
Therefore, the role of molecular chaperones in rod opsin biogene-
sis, quality control and aggregation are potentially important for
disease.
Studies of Drosophila rhodopsin1 (Rh1) identiﬁed NinaA, a pho-
toreceptor speciﬁc ER integral membrane glycoprotein, which acts
as a specialised molecular chaperone and is required for Rh1 mat-
uration [50,51]. Furthermore, Cnx, an ER resident lectin chaperone,
was also required for Rh1 maturation as Cnx mutations led to se-
vere defects in Rh1 expression and disturbance of calcium regula-
tion [52]. More recently, XPORT (exit protein of rhodopsin and TRP)
was identiﬁed as a molecular chaperone that is important for the
biosynthesis and transport of the transient receptor potential
(TRP) channel and Rh1 [53]. While mammalian orthologues of Nin-
aA and XPORT remain to be identiﬁed, the cellular factors that
facilitate the folding, quality control and degradation of mamma-
lian rod opsin have started to be identiﬁed.
In mammalian cells, overexpression of Cnx in combination with
the pharmacological chaperone 11-cis-retinal partially enhanced
the folding of P23H rod opsin and partially inhibited its degrada-
tion [54]. However, Cnx is not required for the maturation of con-
trol wild-type (WT) rod opsin and in cells that lack Cnx, the
degradation of P23H rod opsin was unaffected [55]. Additionally,
Cnx deﬁciency in mice did not affect rod opsin expression or trafﬁc
[56]. Therefore, unlike the situation for ﬂy Rh1, Cnx is not essential
for mammalian rod opsin folding or quality control.
BiP is important for rod opsin biogenesis as its depletion or
dysregulation results in aggregation of WT rod opsin in the ER.
Furthermore, BiP overexpression improved P23H rod opsin ER
mobility, even though it did not improve mutant opsin trafﬁc.
These ﬁndings suggest that chaperone manipulation can be used
as a tool to reduce rod opsin aggregation and highlight a role for
BiP in maintaining rod opsin solubility in the ER [57]. Further-
more, EDEM1 can bind P23H rod opsin and promote its degrada-
tion (Fig. 2A). Importantly, EDEM1 overexpression also enhanced
the folding and trafﬁc of a fraction of P23H rod opsin, and EDEM1
was present in a complex with WT rod opsin in the ER of photo-
receptor cells suggesting that it is important for both WT and mu-
tant rod opsin biogenesis and quality control [58]. Consistent
with these ﬁndings, homologues of human EDEM2 and EDEM3
reduced mutant Rh1 levels and suppressed degeneration in ﬂies
[59].
P23H rod opsin is a substrate of the ERAD effector valosin-con-
taining protein (VCP) [60]. Similarly, studies in Drosophila showed
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mutant Rh1P37H, the ﬂy equivalent of P23H. However, inhibition of
VCP activity suppressed retinal degeneration, suggesting that ERAD
of Rh1P37H might contribute to cell death [61].
If misfolded opsin escapes degradation, it can form inclusions of
aggregated protein. Like many other intracellular inclusions of
aggregated protein, P23H rod opsin inclusions can recruit Hsp70
[62]. However, Hsp70 overexpression did not reduce P23H rod op-
sin inclusion incidence [63]. The neuronal DnaJ (Hsp40) protein
HSJ1b (DNAJB2b) is a molecular chaperone that is targeted to the
cytoplasmic face of the ER and can also associate with mutant
rod opsin inclusions. In photoreceptors, HSJ1b is enriched at sites
of rod opsin synthesis and may be part of a cytoplasmic chaperone
network that participates in rod opsin folding or quality control of
the cytoplasmic domains as HSJ1b overexpression can lead to the
retention in the ER of WT rod opsin [63].
Other components of the proteostasis machinery are likely to be
involved in rod opsin quality control and may be upregulated by
cells to deal with rod opsin misfolding. For example, chemical-ge-
netic activation of IRE1 in mammalian cells promoted the degrada-
tion of mutant misfolded class II rhodopsin [64]. Furthermore,
activation of ATF6 also resulted in reduced levels of class II rod op-
sin mutants, whereas speciﬁc PERK activation led to global reduc-
tions in protein synthesis. Surprisingly, ATF6 activation also led to
reductions in the class I rod opsin mutant S334ter, which is more
often associated with problems of trafﬁc to the OS, not protein
folding [65].
Several studies have examined the potential involvement of ER
stress in retinal degeneration by examining UPR activation
(Fig. 2B). For example, alterations in UPR related genes like BiP
and C/EBP-homologous protein (CHOP) potentially corresponding
to a persistent ER stress state were observed in P23H expressing
transgenic rats [66]. Furthermore, overexpression of BiP alleviated
ER stress and enhanced photoreceptor survival in the P23H rat
model, suggesting that ER stress might be involved in adRP pro-
gression [67]. Moreover, ER stress was observed in the retina of
hT17M Rho mice [68]. Interestingly, more recent ﬁndings raise
the possibility that ER stress may be involved in retinal degenera-
tion arising from causes besides protein misfolding. For example,
ER stress markers and ERAD associated genes were upregulated
in the S334ter rod opsin class I mutant transgenic rat model [69]
and classic UPR markers were upregulated in retina dystrophies
with completely different aetiologies distinct from mutations in
rhodopsin [70]. Therefore, UPR induction might be a common
pathway that is activated in retinal degeneration in different con-
ditions, either as part of the degenerative process or as a cellular
response to photoreceptor cell death.
2.2. Glaucoma
The most common form of glaucoma is primary open angle
glaucoma (POAG) and is frequently associated with elevated intra-
ocular pressure [71]. Three candidate genes, myocilin [72], opti-
neurin [73] and WD repeat domain 36 [74] have been identiﬁed
for familial glaucoma. Myocilin is normally secreted into the aque-
ous humour of the eye and may have a role in the trabecular mesh-
work, a tissue in the anterior segment of the eye that controls
aqueous humour outﬂow and helps regulate intraocular pressure
[75]. Mutations in myocilin lead to the accumulation of mutant
myocilin in the ER of the trabecular meshwork cells and activate
ER stress-induced cell death [76]. The ER protein quality control
program fails to degrade mutant myocilin because of an anoma-
lous interaction with Grp94, which leads to pathogenic conse-
quences. It is not understood why myocilin is not cleared by
ERAD but it has been shown that manipulation of ER chaperones
could have a therapeutic effect, promoting the clearance of aggre-gated proteins through the autophagic route [77]. Optineurin
interacts with Rab8, myosin VI and transferrin receptor (TfR),
suggesting a role in protein trafﬁc. In normal homeostatic situa-
tions the turnover of endogenous optineurin involves mainly the
ubiquitin–proteasome pathway. When optineurin is upregulated
or mutated, the UPS function is compromised, and autophagy is
activated [78].
In experimental glaucoma models, activation of the retinal UPS
has been observed, especially in ganglion cells where ubiquitin
accumulates [79]. Hsp70 is upregulated in a rat model of glaucoma,
suggesting activation of the HSR and a potential response to RGC
stress [80,81]. After retinal insult (N-methyl-D-aspartate (NMDA)-
induced cell death) in rats, levels of HSF1 and Hsp70 increase in
RGCs suggesting a stress response [82]. In zebraﬁsh, which can
regenerate their RGCs, Hsp70 and HSF1 were both upregulated
soon after optic nerve transaction [83]. Furthermore, treatment
with heat shock protein-inducer geranylgeranylacetone (GGA) pro-
tected against RGC death in a glaucoma model [84].
Similarly, the small heat shock protein Hsp27 is highly ex-
pressed in RGCs [85] and throughout the retina, particularly in
the photoreceptors and RPE cells [86]. Hsp27 has been shown to
be speciﬁcally upregulated in RGCs in response to retinal ischemia
[87]. Furthermore, Hsp27 expression was upregulated in RGCs in
rats after optic nerve injury [88] and similarly in the increased
intraocular pressure DBA/J2 mouse model of glaucoma [89]. In hu-
man eyes with POAG or normalpressure glaucoma Hsp27 levels
were elevated in RGCs compared to normal age-matched eyes [90].
2.3. AMD
Oxidative stress has been implicated as a factor in the patho-
genesis of AMD [91]. Other studies suggest that a decline in
autophagy and lysosomal activity is associated with retinal aging
and AMD [92,93]. The role of molecular chaperones in RPE and
AMD is not well understood. Hsc70 is associated with lysosomes
in RPE cells, suggesting a role for chaperone-mediated autophagy
in these cells [94]. However, a proteomic analysis of RPE-derived
mitochondria from AMD patients showed a decrease in the mito-
chondrial Hsp70 (mtHsp70), suggesting a decrease in mitochon-
drial protein import. This could potentially lead to dysregulation
of mitochondrial function [95]. An oxidative stress model in
ARPE19 human RPE cells showed increased Hsp27 and Hsp70
expression after stress. Furthermore, an increase in heat shock pro-
tein expression correlated with cell differentiation and enhanced
resistance to oxidative stress [96]. The small Hsps, alpha-crystal-
lins, are signiﬁcantly upregulated in the RPE in response to heat
shock and oxidative stress [97,98]. Similarly, alpha crystallin is
upregulated in AMD-affected eyes [99]. In a light-induced model
of degeneration, alpha-crystallins were found to be upregulated
in the RPE [100]. Recent work has shown that uptake of alpha-crys-
tallin ‘mini-chaperones’ by cultured RPE cells could reduce apopto-
tic cell death after oxidative stress [101]. The build up of
aggregated material in RPE and drusen may play a role in the acti-
vation of inﬂammatory responses, such as the inﬂammasome, that
are central to the risk of developing AMD. The interaction between
UPS and lysosomal proteolytic pathway could provide an opportu-
nity to manipulate the activities of these degradation pathways for
AMD prevention or treatment.
3. Genomic response to retinal degeneration
Converging evidence from many studies highlight the central
role of the Müller cells in retinal degeneration. Müller cells under-
go reactive gliosis in all forms of retinal injury and disease, which
may contribute to neurodegeneration and impede the regenerative
processes in retinal tissue by the formation of glial scars [102]. A
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ferent types of photoreceptor insults (genetically determined, light
induced and induced retina detachment) showed a characteristic
genomic response, with upregulation of a small number of genes
that overlap in the different models [103]. In particular, among
the induced transcripts, upregulation of endothelin (Edn2) and
ﬁbroblast growth factor 2 (Fgf2) was found in all the models of
photoreceptor degeneration tested. The concomitant induction of
endothelin receptor B (ENDRB) in Müller cells suggests the exis-
tence of a cross talk between photoreceptors and glia, where dam-
aged photoreceptors signal to Müller cells, which in turn produce
Fgf2, a potent neurotrophic factor [103]. An analogous mechanism
driven by Edn2/ENDRB upregulation in the CNS following mechan-
ical trauma has been observed in various rodent models [104].
Edn2 signalling is not necessarily protective. In fact, early stage
expression changes in Edn2 were found also in a model of glau-
coma at a stage where the eyes were indistinguishable from con-
trol eyes based on optic nerve damage. Compromising the Edn2
pathway at this stage was found to be signiﬁcantly protective from
glaucoma in DBA/2J mice [105].
Another active player in the retina response to damage, linked
to the Edn2 pathway, is leukaemia inhibitory factor (LIF). This mol-
ecule was strongly induced in the retina of P23H transgenic models
[106]. Photoreceptor injury induced LIF expression in a subset of
Müller glia cells in the INL of the retina. Ablation of LIF in this mod-
el prevented upregulation of genes like Fgf2 and Edn2 in the pho-
toreceptor cells. Collectively, the data support the role of neuronal
survival factors, like LIF, initiating an intrinsic protective mecha-
nism that includes Edn2 signalling to support photoreceptor cell
survival.
4. Therapeutic approaches and concluding remarks
At present there are no effective treatments for most retinal
degenerations. The need for an effective treatment for retinal
diseases, coupled to the development of appropriate animal
models has stimulated a variety of potential therapeutic direc-
tions. These include preventive strategies that aim to counteract
the underlying disease mechanisms, either by manipulating cel-
lular pathways or genetic modiﬁcation by gene silencing and/or
gene replacement; strategies that do not deal with the cause of
the disease, such as cell death prevention with neurotrophic fac-
tors; or cell replacement by transplantation and artiﬁcial vision.
This section will discuss the strategies that target the cell stress
machinery in order to alleviate the cell stress response in retinal
degenerations.
Several compounds that can alter either the cellular milieu or
target directly the protein structure have been shown to protect
cells from the toxic effects of aberrant misfolded proteins, such
as those associated with retinal degenerations. These compounds
include pharmacological chaperones, kosmotropes, molecular
chaperone inducers and those that manipulate autophagic path-
ways. For instance, pharmacological chaperones often share struc-
tural similarities with natural receptor ligands (agonists,
antagonists, inverse agonists) and can stabilise native states. They
can penetrate the cell, diffuse to the ER and bind to newly synthes-
ised proteins, shifting the folding equilibrium in favour of native or
folded conformation. 11-cis retinal and 9-cis retinal can act as
pharmacological chaperones for rod opsin and improve P23H fold-
ing in cells [54,62,107–109].
Kosmotropes, also known as chemical chaperones, are small,
low molecular weight, compounds that stabilise proteins and
hydrophobic aggregates. A range of chemical chaperones such as
trimethylamine N-oxide (TMAO) and 4-phenylbutyric acid (4-
PBA) reduced aggregation and cell death associated with P23H
rod opsin in cells [108]. In glaucoma, TMAO facilitated the foldingand secretion of myocilin in vitro [110], while PBA reduced aggre-
gation and apoptosis associated with myocilin mutation in mice
[111] and in cells [112]. When tauroursodeoxcholic acid (TUDCA),
a major component of bear bile that can act as a chemical chaper-
one, was tested in several animal models of retinal degeneration, it
prevented apoptosis and preserved the structure and function of
photoreceptor cells [113–115]. Interestingly, TUDCA has been
found to be protective in other ocular cell types including RGCs
and lens epithelial cells which are compromised in cataract
[116,117].
Barbe et al. (1988) showed that inducing a pre-conditioning
hyperthermia in rats could reduce or prevent light-induced photo-
receptor cell loss, suggesting that increasing Hsp and molecular
chaperone production as a potential treatment for retinal disorders
[118]. Indeed, chaperone inducers such as radicicol, geldanamycin,
and its analogue 17-allylamino-17-demethoxygeldanamycin (17-
AAG) were effective in reducing aggregation and/or cell death in
a P23H rod opsin cell model [108]. In another study, administration
of 17-AAG, coupled to manipulation of the BRB by claudin-5 siRNA,
in an adRP (RP10) mouse model protected photoreceptor cells by
inducing Hsp expression and reducing protein aggregation
associated with the disease [119]. Additionally, geranylgeranylace-
tone and canavanine have been found to be protective in a rat
glaucoma model and streptozotocin-diabetic retinopathy rat
model respectively [120,121]. Furthermore, the progress in
gene-replacement strategies using viral-mediated delivery to treat
retinal degenerations with knownmutations has paved the way for
viral-mediated manipulation of molecular chaperones to treat
retinal degeneration associated with protein misfolding. For exam-
ple, viral-mediated overexpression of BiP reduced photo-
receptor cell death and improved visual function in a P23H rat
model [67].
Another approach to alleviate retinal cell death is to manipu-
late the mTOR signalling pathway and stimulate autophagy. One
such compound, rapamycin, has been shown to enhance the
clearance of aggregation-prone proteins and enhance the degra-
dation of P23H rod opsin [108,122]. Administration of rapamycin
to a rat model with some AMD-like pathology suppressed retinal
degeneration [123], and reduced choroidal and retinal neovascu-
larisation in photocoagulation- and hyperoxia/hypoxia-induced
mice [124].
Alternative therapeutic approaches include the deacetylase
inhibitor valproic acid, which is currently moving towards clin-
ical trials but its applicability is questioned due to its side ef-
fects, calcium channel blockers, antioxidants and neurotrophic
factors which can be used to slow retinal degeneration
[54,125–128].
Despite encouraging results from the above treatments, re-
search is still on-going and currently the only recommended treat-
ment for RP is vitamin A supplementation alone or in combination
with docosahexaenoic acid to modestly delay photoreceptor
degeneration [129]. However, high dose vitamin A could in itself
be problematic and this needs to be carefully considered. The
advantages of investigating the most accessible part of the CNS
have opened up a variety of therapeutic directions for retinal
degeneration. A thorough understanding of the molecular mecha-
nisms underlying retinal degenerations as well as identiﬁcation
of all the genetic causes of these disorders will improve the pros-
pect of therapies.Acknowledgments
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